Mindy Lee-Olsen, 408-731-5523 (Media)Vice President, Marketing ServicesorDoug Farrell, 408-731-5285 (Investors)Vice President, Investor Relations (NASDAQ:AFFX) announced today the availability of ...
Affymetrix Inc. and LineaGen Inc. have announced that a team of prominent researchers at the University of Utah and Vanderbilt University are leveraging Utah’s deep domain expertise in human genetic ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that the Wellcome Trust Sanger Institute has developed a catalog of structural genomic changes in almost 800 cancer ...
SANTA CLARA, Calif. & PARIS--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ: AFFX) and ScreenCell, a privately-held company, today announced the signing of a worldwide distribution agreement for ScreenCell ...
Affymetrix, Inc. has announced that its Axiom® high-throughput genotyping technology was instrumental in two transplantation peer-reviewed publications issued this month by an international team of ...
Initial focus will be on tools to help cancer diagnosis. Affymetrix and Ipsogen signed a Powered by Affymetrix™ (PbA) agreement. With this transaction, Ipsogen gains nonexclusive access to Affymetrix ...
Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...
Affymetrix Inc. (Nasdaq:AFFX) and Baylor College of Medicine announced today that Baylor has obtained a non-exclusive, worldwide license to a number of Affymetrix patents covering comparative genomic ...
Unique and optimized solution provides highly sensitive and reproducible RNA amplification and labeling from archived FFPE samples for biomarker discovery and validation on industry-leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results